SNY vs TVTX
Sanofi vs Travere Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TVTX
Travere Therapeutics, Inc.
67
Buy
| Metric | SNY | TVTX |
|---|
| AI Score |
68
|
67
|
| Price |
$43.70
|
$62.07
|
| P/E Ratio |
23.09×
|
-138.09×
|
| ROE |
10.9%
|
-22.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.8%
|
94.4%
|
| Debt / Equity |
0.34×
|
25.16×
|
| Dividend Yield |
5.5%
|
0.0%
|
| RSI (14) |
56.9
|
64.5
|
| Beta |
0.278
|
1.042
|
| Expected Upside |
+3.5%
|
—
|
AI Committee View
Current Innellis committee reasoning for SNY versus TVTX.
SNY leads by 1 points.
SNY scores 68/100 (Buy) versus TVTX at 67/100 (Buy).
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.4% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
TVTX Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 19.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 19.4% signals elevated volatility — Risk